{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:36Z","timestamp":1791216576154,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00108-023-01516-y","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T08:02:27Z","timestamp":1684915347000},"page":"546-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metastasiertes kolorektales Karzinom\u00a0\u2013 moderne Therapiestrategien und -sequenzen","Metastatic colorectal cancer\u2014Modern treatment strategies and sequences"],"prefix":"10.1007","volume":"64","author":[{"given":"T. J.","family":"Ettrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Schuhbaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Seufferlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"1516_CR1","first-page":"281","volume":"118","author":"R Cardoso","year":"2021","unstructured":"Cardoso\u00a0R, Zhu\u00a0A, Guo\u00a0F et al (2021) Incidence and mortality of proximal and distal colorectal cancer in Germany-trends in the era of screening colonoscopy. Dtsch Arztebl Int 118:281\u2013287","journal-title":"Dtsch Arztebl Int"},{"key":"1516_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12885-016-2290-5","volume":"16","author":"TD Christensen","year":"2016","unstructured":"Christensen\u00a0TD, Spindler\u00a0KL, Palshof\u00a0JA et\u00a0al (2016) Systematic review: brain metastases from colorectal cancer\u2014incidence and patient characteristics. BMC Cancer 16:260","journal-title":"BMC Cancer"},{"key":"1516_CR3","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/jnci\/djh275","volume":"96","author":"JB O\u2019Connell","year":"2004","unstructured":"O\u2019Connell\u00a0JB, Maggard\u00a0MA, Ko\u00a0CY (2004) Colon cancer survival rates with the new American joint committee on cancer sixth edition staging. J\u00a0Natl Cancer Inst 96:1420\u20131425","journal-title":"J Natl Cancer Inst"},{"key":"1516_CR4","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","volume":"27","author":"R Adam","year":"2009","unstructured":"Adam\u00a0R, Wicherts\u00a0DA, de Haas\u00a0RJ et\u00a0al (2009) Patients with initially unresectable colorectal liver metastases: is there a\u00a0possibility of cure? J\u00a0Clin Oncol 27:1829\u20131835","journal-title":"J Clin Oncol"},{"key":"1516_CR5","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.2007.15.7297","volume":"26","author":"R Adam","year":"2008","unstructured":"Adam\u00a0R, de Haas\u00a0RJ, Wicherts\u00a0DA et\u00a0al (2008) Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J\u00a0Clin Oncol 26:3672\u20133680","journal-title":"J Clin Oncol"},{"key":"1516_CR6","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz\u00a0S, Chang\u00a0GJ, Overman\u00a0MJ et\u00a0al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J\u00a0Clin Oncol 27:3677\u20133683","journal-title":"J Clin Oncol"},{"key":"1516_CR7","volume-title":"Wirksamkeit der Versorgung in onkologischen Zentren (WiZen)","author":"O Schoffer","year":"2022","unstructured":"Schoffer\u00a0O, Roessler\u00a0M, Bierbaum\u00a0V (2022) Wirksamkeit der Versorgung in onkologischen Zentren (WiZen)"},{"key":"1516_CR8","volume-title":"S3-Leitlinie Kolorektales Karzinom, Langversion 2.1","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF)","year":"2019","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) (2019) S3-Leitlinie Kolorektales Karzinom, Langversion 2.1 (AWMF Registrierungsnummer: 021\/007OL)"},{"key":"1516_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/SLA.0000000000003848","volume":"273","author":"K Boudjema","year":"2021","unstructured":"Boudjema\u00a0K, Locher\u00a0C, Sabbagh\u00a0C et al (2021) Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial. Ann Surg 273:49\u201356","journal-title":"Ann Surg"},{"key":"1516_CR10","doi-asserted-by":"publisher","first-page":"LBA3507","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3507","volume":"40","author":"NN Rahbari","year":"2022","unstructured":"Rahbari\u00a0NN, Biondo\u00a0S, Fei\u00dft\u00a0M et\u00a0al (2022) Randomized clinical trial on resection of the primary tumor versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases. J\u00a0Clin Oncol 40:LBA3507","journal-title":"J Clin Oncol"},{"key":"1516_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong\u00a0Y, Fortner\u00a0J, Sun\u00a0RL et\u00a0al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001\u00a0consecutive cases. Ann Surg 230:309\u2013318 (discussion 318\u2013321)","journal-title":"Ann Surg"},{"key":"1516_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/SLA.0b013e3182902b6e","volume":"259","author":"ZZ Hamady","year":"2014","unstructured":"Hamady\u00a0ZZ, Lodge\u00a0JP, Welsh\u00a0FK et al (2014) One-millimeter cancer-free margin is curative for colorectal liver metastases: a\u00a0propensity score case-match approach. Ann Surg 259:543\u2013548","journal-title":"Ann Surg"},{"key":"1516_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s13244-017-0558-1","volume":"8","author":"A Gotra","year":"2017","unstructured":"Gotra\u00a0A, Sivakumaran\u00a0L, Chartrand\u00a0G et\u00a0al (2017) Liver segmentation: indications, techniques and future directions. Insights Imaging 8:377\u2013392","journal-title":"Insights Imaging"},{"key":"1516_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.hpb.2016.06.006","volume":"18","author":"KP Cieslak","year":"2016","unstructured":"Cieslak\u00a0KP, Bennink\u00a0RJ, de Graaf\u00a0W et\u00a0al (2016) Measurement of liver function using hepatobiliary scintigraphy improves risk assessment in patients undergoing major liver resection. HPB (Oxford) 18:773\u2013780","journal-title":"HPB (Oxford)"},{"key":"1516_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1245\/s10434-012-2864-7","volume":"20","author":"J Shindoh","year":"2013","unstructured":"Shindoh\u00a0J, Tzeng\u00a0CW, Aloia\u00a0TA et\u00a0al (2013) Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 20:2493\u20132500","journal-title":"Ann Surg Oncol"},{"key":"1516_CR16","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1055\/s-0043-121106","volume":"55","author":"W Schmiegel","year":"2017","unstructured":"Schmiegel\u00a0W, Buchberger\u00a0B, Follmann\u00a0M et al (2017) S3-Leitlinie \u2013 Kolorektales Karzinom. Z\u00a0Gastroenterol 55:1344\u20131498","journal-title":"Z Gastroenterol"},{"key":"1516_CR17","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","volume":"28","author":"N Boeckx","year":"2017","unstructured":"Boeckx\u00a0N, Koukakis\u00a0R, Op de Beeck\u00a0K et al (2017) Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol 28:1862\u20131868","journal-title":"Ann Oncol"},{"key":"1516_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar\u00a0S, Stintzing\u00a0S, Ciardiello\u00a0F et al (2017) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE\u20113 trials. JAMA Oncol 3:194\u2013201","journal-title":"JAMA Oncol"},{"key":"1516_CR19","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","volume":"32","author":"F Rivera","year":"2017","unstructured":"Rivera\u00a0F, Karthaus\u00a0M, Hecht\u00a0JR et al (2017) Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 32:1179\u20131190","journal-title":"Int J Colorectal Dis"},{"key":"1516_CR20","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini\u00a0C, Loupakis\u00a0F, Antoniotti\u00a0C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315","journal-title":"Lancet Oncol."},{"key":"1516_CR21","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"A Falcone","year":"2007","unstructured":"Falcone\u00a0A, Ricci\u00a0S, Brunetti\u00a0I et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J\u00a0Clin Oncol 25:1670\u20131676","journal-title":"J Clin Oncol"},{"key":"1516_CR22","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.19.01340","volume":"37","author":"DP Modest","year":"2019","unstructured":"Modest\u00a0DP, Martens\u00a0UM, Riera-Knorrenschild\u00a0J et al (2019) FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109). J\u00a0Clin Oncol 37:3401\u20133411","journal-title":"J Clin Oncol"},{"key":"1516_CR23","doi-asserted-by":"publisher","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.017","volume":"33","author":"MJG Bond","year":"2022","unstructured":"Bond\u00a0MJG, Bolhuis\u00a0K, Loosveld\u00a0OJL et al (2022) LBA21 FOLFOX\/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS\/BRAFV600E wild-type tumour: phase III CAIRO5\u00a0study of the Dutch colorectal cancer group. Ann Oncol 33:S1389","journal-title":"Ann Oncol"},{"key":"1516_CR24","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9\u00a0T, Shiu\u00a0KK, Kim\u00a0TW et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N\u00a0Engl J Med 383:2207\u20132218","journal-title":"N Engl J Med"},{"key":"1516_CR25","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1200\/JCO.2020.38.15_suppl.4005","volume":"38","author":"Y Kanemitsu","year":"2020","unstructured":"Kanemitsu\u00a0Y, Shimizu\u00a0Y, Mizusawa\u00a0J et\u00a0al (2020) A randomized phase II\/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: JCOG0603\u00a0study. J\u00a0Clin Oncol 38:4005\u20134005","journal-title":"J Clin Oncol"},{"key":"1516_CR26","doi-asserted-by":"publisher","first-page":"4906","DOI":"10.1200\/JCO.2008.17.3781","volume":"26","author":"E Mitry","year":"2008","unstructured":"Mitry\u00a0E, Fields\u00a0AL, Bleiberg\u00a0H et\u00a0al (2008) Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a\u00a0pooled analysis of two randomized trials. J\u00a0Clin Oncol 26:4906\u20134911","journal-title":"J Clin Oncol"},{"key":"1516_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2018.10.003","volume":"106","author":"M Imanishi","year":"2019","unstructured":"Imanishi\u00a0M, Yamamoto\u00a0Y, Hamano\u00a0Y et al (2019) Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a\u00a0propensity score-matched analysis. Eur J Cancer 106:69\u201377","journal-title":"Eur J Cancer"},{"key":"1516_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard\u00a0JY, Oliner\u00a0KS, Siena\u00a0S et al (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023\u20131034","journal-title":"N. Engl. J. Med."},{"key":"1516_CR29","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1001\/jama.2010.1535","volume":"304","author":"W De Roock","year":"2010","unstructured":"De Roock\u00a0W, Jonker\u00a0DJ, Di Nicolantonio\u00a0F et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812\u20131820","journal-title":"JAMA"},{"key":"1516_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann\u00a0V, von Weikersthal\u00a0LF, Decker\u00a0T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a\u00a0randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"key":"1516_CR31","doi-asserted-by":"publisher","first-page":"LBA1","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1","volume":"40","author":"T Yoshino","year":"2022","unstructured":"Yoshino\u00a0T, Watanabe\u00a0J, Shitara\u00a0K et al (2022) Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial. J\u00a0Clin Oncol 40:LBA1","journal-title":"J Clin Oncol"},{"key":"1516_CR32","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold\u00a0D, Lueza\u00a0B, Douillard\u00a0JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713\u20131729","journal-title":"Ann Oncol"},{"key":"1516_CR33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01225","author":"C Cremolini","year":"2020","unstructured":"Cremolini\u00a0C, Antoniotti\u00a0C, Stein\u00a0A et al (2020) Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.01225","journal-title":"J Clin Oncol"},{"key":"1516_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini\u00a0C, Antoniotti\u00a0C, Rossini\u00a0D et al (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a\u00a0multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21:497\u2013507","journal-title":"Lancet Oncol"},{"key":"1516_CR35","doi-asserted-by":"publisher","first-page":"LBA3505","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA3505","volume":"40","author":"C Cremolini","year":"2022","unstructured":"Cremolini\u00a0C, Rossini\u00a0D, Lonardi\u00a0S et al (2022) Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI\/PAN) versus mFOLFOX6\/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): results of the phase III randomized TRIPLETE study by GONO. J\u00a0Clin Oncol 40:LBA3505","journal-title":"J Clin Oncol"},{"key":"1516_CR36","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham\u00a0D, Lang\u00a0I, Marcuello\u00a0E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077\u20131085","journal-title":"Lancet Oncol"},{"key":"1516_CR37","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","volume":"377","author":"MT Seymour","year":"2011","unstructured":"Seymour\u00a0MT, Thompson\u00a0LC, Wasan\u00a0HS et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749\u20131759","journal-title":"Lancet"},{"key":"1516_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12885-017-3526-8","volume":"17","author":"SB Winther","year":"2017","unstructured":"Winther\u00a0SB, \u00d6sterlund\u00a0P, Berglund \u00c5 et al (2017) Randomized study comparing full dose monotherapy (S\u20111 followed by irinotecan) and reduced dose combination therapy (S-1\/oxaliplatin followed by S\u20111\/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer 17:548","journal-title":"BMC Cancer"},{"issue":"13","key":"1516_CR39","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S1470-2045(15)00042-X","volume":"16","author":"S Hegewisch-Becker","year":"2015","unstructured":"Hegewisch-Becker\u00a0S, Graeven\u00a0U, Lerchenmuller\u00a0CA et al (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 16(13):1355\u20131369. https:\/\/doi.org\/10.1016\/S1470-2045(15)00042-X","journal-title":"Lancet Oncol"},{"issue":"9980","key":"1516_CR40","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","volume":"385","author":"LH Simkens","year":"2015","unstructured":"Simkens\u00a0LH, van Tinteren\u00a0H, May\u00a0A et\u00a0al (2015) Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal cancer group. Lancet 385(9980):1843\u20131852. https:\/\/doi.org\/10.1016\/S0140-6736(14)62004-3","journal-title":"Lancet"},{"key":"1516_CR41","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","volume":"33","author":"T Andr\u00e9","year":"2022","unstructured":"Andr\u00e9\u00a0T, Lonardi\u00a0S, Wong\u00a0KYM et al (2022) Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4\u2011year follow-up from CheckMate 142. Ann Oncol 33:1052\u20131060","journal-title":"Ann Oncol"},{"key":"1516_CR42","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman\u00a0MJ, McDermott\u00a0R, Leach\u00a0JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2\u00a0study. Lancet Oncol 18:1182\u20131191","journal-title":"Lancet Oncol"},{"key":"1516_CR43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti\u00a0C, Rossini\u00a0D, Pietrantonio\u00a0F et al (2022) Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a\u00a0multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 23:876\u2013887","journal-title":"Lancet Oncol"},{"key":"1516_CR44","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters\u00a0M, Price\u00a0TJ, Cervantes\u00a0A et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J\u00a0Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"},{"key":"1516_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx393.004","author":"J Bennouna","year":"2017","unstructured":"Bennouna\u00a0J, Hiret\u00a0S, Borg\u00a0C et al (2017) Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): final analysis of a French randomized, multicenter, phase II study (PRODIGE 18). Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx393.004","journal-title":"Ann Oncol"},{"key":"1516_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna\u00a0J, Sastre\u00a0J, Arnold\u00a0D et\u00a0al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a\u00a0randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"1516_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","volume":"50","author":"J Tabernero","year":"2014","unstructured":"Tabernero\u00a0J, Van Cutsem\u00a0E, Lakomy\u00a0R et\u00a0al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50:320\u2013331","journal-title":"Eur J Cancer"},{"key":"1516_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero\u00a0J, Yoshino\u00a0T, Cohn\u00a0AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a\u00a0fluoropyrimidine (RAISE): a\u00a0randomised, double-blind, multicentre, phase 3\u00a0study. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"1516_CR49","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman\u00a0MJ, Lonardi\u00a0S, Wong\u00a0KYM et al (2018) Durable clinical benefit with nivolumab plus Ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J\u00a0Clin Oncol 36:773\u2013779","journal-title":"J Clin Oncol"},{"key":"1516_CR50","doi-asserted-by":"publisher","first-page":"4001","DOI":"10.1200\/JCO.2020.38.15_suppl.4001","volume":"38","author":"S Kopetz","year":"2020","unstructured":"Kopetz\u00a0S, Grothey\u00a0A, Cutsem\u00a0EV et al (2020) Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a\u00a0randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J\u00a0Clin Oncol 38:4001\u20134001","journal-title":"J Clin Oncol"},{"key":"1516_CR51","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz\u00a0S, Grothey\u00a0A, Yaeger\u00a0R et al (2019) Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N\u00a0Engl J Med 381:1632\u20131643","journal-title":"N Engl J Med"},{"key":"1516_CR52","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey\u00a0A, Van Cutsem\u00a0E, Sobrero\u00a0A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312","journal-title":"Lancet"},{"key":"1516_CR53","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer\u00a0RJ, Van Cutsem\u00a0E, Falcone\u00a0A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N\u00a0Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"1516_CR54","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer\u00a0P, Yilmaz\u00a0M, M\u00f6ller\u00a0S et al (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21:412\u2013420","journal-title":"Lancet Oncol"},{"key":"1516_CR55","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/j.annonc.2022.08.021","volume":"33","author":"NA Dasari","year":"2022","unstructured":"Dasari\u00a0NA, Lonardi\u00a0S, Garcia-Carbonero\u00a0R et al (2022) LBA25 FRESCO-2: a global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann Oncol 33:1391\u20131392","journal-title":"Ann Oncol"},{"key":"1516_CR56","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/DDDT.S85567","volume":"9","author":"M Suenaga","year":"2015","unstructured":"Suenaga\u00a0M, Mizunuma\u00a0N, Matsusaka\u00a0S et al (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 9:3099\u20133108","journal-title":"Drug Des Devel Ther"},{"key":"1516_CR57","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena\u00a0S, Di Bartolomeo\u00a0M, Raghav\u00a0K et al (2021) Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a\u00a0multicentre, open-label, phase 2 trial. Lancet Oncol 22:779\u2013789","journal-title":"Lancet Oncol"},{"key":"1516_CR58","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1200\/JCO.2021.39.15_suppl.3505","volume":"39","author":"T Yoshino","year":"2021","unstructured":"Yoshino\u00a0T, Bartolomeo\u00a0MD, Raghav\u00a0KPS et al (2021) Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a\u00a0phase 2, multicenter, open-label study (DESTINY-CRC01). J\u00a0Clin Oncol 39:3505\u20133505","journal-title":"J Clin Oncol"},{"key":"1516_CR59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2030638","volume":"384","author":"AH Nassar","year":"2021","unstructured":"Nassar\u00a0AH, Adib\u00a0E, Kwiatkowski\u00a0DJ (2021) Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type. N\u00a0Engl J Med 384:185\u2013187","journal-title":"N Engl J Med"},{"issue":"5","key":"1516_CR60","doi-asserted-by":"publisher","first-page":"S1283","DOI":"10.1016\/annonc\/annonc741","volume":"32","author":"J Weiss","year":"2021","unstructured":"Weiss\u00a0J, Yaeger\u00a0RD, Johnson\u00a0ML et al (2021) KRYSTAL-1: adagrasib (MRTX849) as monotherapy or combined with cetuximab (cetux) in patients (pts) with colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol 32(5):S1283\u2013S1346. https:\/\/doi.org\/10.1016\/annonc\/annonc741","journal-title":"Ann Oncol"},{"key":"1516_CR61","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen\u00a0CB, Krebs\u00a0MG, Le Tourneau\u00a0C et al (2021) Genomic context of NTRK1\/2\/3 fusion-positive tumours from a\u00a0large real-world population. NPJ Precis Oncol 5:69","journal-title":"NPJ Precis Oncol"},{"key":"1516_CR62","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon\u00a0A, Laetsch\u00a0TW, Kummar\u00a0S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N\u00a0Engl J Med 378:731\u2013739","journal-title":"N Engl J Med"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01516-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01516-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01516-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T12:02:55Z","timestamp":1685620975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01516-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01516-y","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]},"assertion":[{"value":"5 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>T.J.\u00a0Ettrich<\/b>: A. Finanzielle Interessen: Forschungsf\u00f6rderung: Servier.\u00a0\u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmender: Servier, Ipsen, Lilly,  AstraZeneca, Bayer, BMS, Daiichi Sankyo, Eisai, Incyte, Ipsen, Lilly, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi, Servier.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellter, Universit\u00e4tsklinikum Ulm | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft (AIO), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Deutsche Krebsgesellschaft (DKG). <b>J.S.\u00a0Schuhbaur<\/b>: A. Finanzielle Interessen: J.S.\u00a0Schuhbaur gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B. Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin der Inneren Medizin, Universit\u00e4tsklinikum Ulm, Klinik f\u00fcr Innere Medizin\u00a0I. <b>T.\u00a0Seufferlein<\/b>: A. Finanzielle Interessen: Studienprojekt: Lilly, Boehringer, BMS, Sanofi.\u00a0\u2013 Honorare f\u00fcr Vortr\u00e4ge: Amgen, Bayer, Falk Foundation, AstraZeneca, Pierre Fabre, Servier.\u00a0\u2013 Beratung: Lilly, Bayer, Servier, AstraZeneca, Pierre Fabre, Cantargia, Mirati, Olympus.\u00a0\u2013 B. Nichtfinanzielle Interessen: \u00c4rztlicher Direktor, Klinik f\u00fcr Innere Medizin\u00a0I, Universit\u00e4tsklinikum Ulm; Vorstandsmitglied Deutsche Krebsgesellschaft (DKG); Vorstandsmitglied Deutsche Gesellschaft f\u00fcr Koloproktologie; Generalsekret\u00e4r European Society for Digestive Oncology | Mitgliedschaften: DGVS, ASCO, ESMO, DKG, United European Gastroenterology (UEG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}